Netherlands · Delayed Price · Currency is EUR DSM-Firmenich AG Earnings Call Transcripts
Fiscal Year 2026
-
Solid Q1 with 4% volume-driven sales growth and strong Perfumery and Beauty performance. Full-year outlook reaffirmed, margins expected to improve as FX and cost impacts are managed. Dual listing on SIX Swiss Exchange announced to broaden investor base.
-
The company has completed its transformation, focusing on specialty ingredients and creation capabilities, with strong progress in synergies, sustainability, and financial performance. 2026–2028 targets include 2%-4% organic sales growth (rising to 4%-6% plus Bovaer), EBITDA margin of 20%-23%, and cash conversion above 14%.
-
Divestment of Animal Nutrition & Health to CVC for EUR 2.2 billion enables a focused consumer business, with a 20% retained stake and favorable vitamin supply terms. Share buyback and stable dividend reflect confidence in future cash flow, while restated financials and strategic targets will guide the next phase.
Fiscal Year 2025
-
Divestment of ANH refocuses the business on nutrition, health, and beauty, with 3% organic sales growth in 2025 and a resilient EBITDA margin near 20%. Cash conversion remains strong, and midterm targets for growth and margin are unchanged, with an upward revision to the cash target expected.
-
Q3 saw 2% organic sales growth and a 10% adjusted EBITDA increase, with strong margins in core segments despite macro headwinds. Full-year 2025 EBITDA is guided at EUR 2.3 billion, reflecting FX and vitamin price pressures, while strategic synergies and cash performance remain robust.
-
H1 2025 delivered 7% organic sales growth, margin expansion, and strong segment performance, with integration synergies and portfolio tuning supporting results. Outlook for 2025 remains confident despite FX headwinds, with no major M&A planned and continued focus on innovation and high-growth segments.
-
Q1 2025 delivered 8% organic growth and a 40% EBITDA increase, driven by strong core business performance and a temporary vitamin impact. Strategic divestments, a €1 billion share buyback, and a €750 million bond strengthened the balance sheet, with full-year EBITDA guidance maintained at €2.4 billion.
Fiscal Year 2024
-
Delivered strong 2024 results with 6% organic growth, a 20% EBITDA increase, and over €1.5 billion in cash generation. Portfolio transformation advanced with key divestments, and 2025 guidance targets at least €2.4 billion EBITDA, driven by synergies and innovation.
-
Strong organic growth and margin expansion drove a 32% year-over-year EBITDA increase in Q3, with all business units contributing and free cash flow sharply higher. Upgraded full-year EBITDA guidance to EUR 2.1 billion, supported by synergy realization, disciplined cash management, and positive market momentum.
-
The company highlighted its science-driven innovation, global reach, and strong sustainability focus, reporting robust growth across all business units. Plans include separating the Animal Nutrition & Health segment by 2025, targeting EUR 10 billion in sales and higher margins.
-
First half saw strong organic growth, margin expansion, and robust cash flow, driven by synergy realization and segment outperformance, especially in Perfumery & Beauty and Taste, Texture & Health. Full-year Adjusted EBITDA outlook was upgraded to around EUR 2 billion, with continued focus on portfolio tuning and sustainability.
-
The company is accelerating its transformation by divesting Animal Nutrition & Health, focusing on high-growth, science-driven segments in health, nutrition, and beauty. Midterm targets include 5%-7% organic growth, 22%-23% EBITDA margin, and at least 10% cash conversion, supported by strong innovation, sustainability commitments, and disciplined capital allocation.